Desktop Site
|
23 Apr 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Get Quote
*
Notices
|
S&P
BSE SENSEX
73,738.45
+89.83
+0.12 %
Corporate Announcement
Security Code
524804
Company
Aurobindo Pharma Ltd
Exchange Received Time
13/11/2019 21:39:35
Exchange Disseminated Time
13/11/2019 21:39:41
Time Taken
00:00:06
Sub: Completion Of USFDA Inspection At Our Unit IV - Reg., |
11/13/2019 9:39:36 PM
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (US FDA) inspected Company's Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad, from 4th to 13th November 2019. At the end of the inspection, we have been issued a 'Form 483' with 14 observations. We believe that none of these observations are related to data integrity issues. The Company will respond to the US FDA within the stipulated timeline.
Attachment
<< Back
Recently Viewed